Dr. James E. Pennington M.D. serves as Chief Medical Officer of the Company. Dr. Pennington served as Senior Clinical Fellow from 2010 to 2018 and as Executive Vice President and Chief Medical Officer from 2007 to 2010 at Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH). From 2004 to 2007, Dr. Pennington served as Executive Vice President and Chief Medical Officer at CoTherix, Inc., and has held various executive positions at a number of pharmaceutical companies, including InterMune Inc., Shaman Pharmaceuticals and Bayer Corporation. He has served on several editorial boards, and has authored numerous original research publications and reviews. Dr. Pennington is currently a Clinical Professor of Medicine with the University of California San Francisco, where he has taught since 1986. Prior to that, he was a professor at Harvard Medical School. Dr. Pennington received a Bachelor of Arts from the University of Oregon and a Doctor of Medicine from the University of Oregon School of Medicine, and is Board Certified in internal medicine and infectious diseases.
As the Chief Medical Officer of AzurRx BioPharma Inc, the total compensation of James Pennington at AzurRx BioPharma Inc is $445,000. There are 1 executives at AzurRx BioPharma Inc getting paid more, with James R. Sapirstein R.Ph., M.B.A. having the highest compensation of $622,005.
James Pennington is 77, he's been the Chief Medical Officer of AzurRx BioPharma Inc since 2018. There are 1 older and 7 younger executives at AzurRx BioPharma Inc. The oldest executive at AzurRx BioPharma Inc is Vern Schramm, 78, who is the Independent Director.
James's mailing address filed with the SEC is Brooklyn, NY 11226, USA.
Over the last 8 years, insiders at AzurRx BioPharma Inc have traded over $510,400 worth of AzurRx BioPharma Inc stock and bought 335,700 units worth $727,436 . The most active insiders traders include Charles J Casamento, Edmund Burke Jr. Ross és Partners Llcbalk Matthew Pe.... On average, AzurRx BioPharma Inc executives and independent directors trade stock every 82 days with the average trade being worth of $262,052. The most recent stock trade was executed by Johan M. Spoor on 28 December 2018, trading 38,583 units of AZRX stock currently worth $50,158.
AzurRx BioPharma Inc executives and other stock owners filed with the SEC include: